Press Releases

Date Title
06/12/19
Summary ToggleT2 Biosystems to Highlight its Products and Technology at Upcoming Medical Meetings Printer Friendly Version LEXINGTON, Mass. , June 12, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it will highlight its rapid molecular diagnostic products and technology, including the
06/10/19
Summary ToggleT2 Biosystems Reports Granting of Inducement Awards Printer Friendly Version LEXINGTON, Mass. , June 10, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on June 4, 2019 it issued inducement awards to two new
06/06/19
Summary ToggleNew Studies Highlight Potential for T2Bacteria and T2Candida Panels to Improve Outcomes and be Cost-Effective for Sepsis Patients in the Medical Intensive Care Unit and Emergency Department Printer Friendly Version LEXINGTON, Mass. , June 06, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today the publication of two independent, peer-reviewed studies highlighting the potential of the
05/24/19
Summary ToggleT2 Biosystems to Participate in Singular Research Spring Select Web Call Printer Friendly Version Reiterates 2019 revenue and new contract guidance LEXINGTON, Mass. , May 24, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that John McDonough , chief executive
05/23/19
Summary ToggleRobust Clinical Data and Positive Customer Experience with T2Bacteria and T2Candida Panels Highlighted at Recent Medical Meetings Printer Friendly Version Presentations at ECCMID and MAD-ID meetings demonstrate clinically actionable results and cost savings achieved with these panels Real-world experience reinforces multi-day time advantage demonstrated in the T2Bacteria 1,427-patient pivotal study, as compared to post-blood culture species
05/14/19
Summary TogglePublication in Annals of Internal Medicine® Reveals T2Bacteria® Panel as the First Direct-from-Blood, Non-Culture Test that Rapidly Diagnoses Bacterial Bloodstream Infections Printer Friendly Version Study demonstrates patients tested with T2Bacteria can get started on the proper therapy sooner LEXINGTON, Mass. , May 14, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today
05/13/19
Summary ToggleT2 Biosystems Reports Granting of Inducement Awards Printer Friendly Version LEXINGTON, Mass. , May 13, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on May 8, 2019 it issued inducement awards to three new
05/08/19
Summary ToggleT2 Biosystems to Showcase Breakthrough Rapid Diagnostics During 22nd Annual MAD-ID Meeting in Orlando, Florida Printer Friendly Version Company will highlight how direct-from-whole blood innovations—the T2Bacteria, T2Candida and T2Resistance panels—can be implemented into antimicrobial stewardship programs LEXINGTON, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), an emerging leader in the development
05/02/19
Summary ToggleT2 Biosystems Reports First Quarter 2019 Financial Results and Provides Corporate Update Printer Friendly Version Exceeds Q1 Guidance with Delivery of $1.8 Million in Revenue and 11 New Instrument Contracts Confirms 2019 Guidance of a Doubling of Revenue and Securing 70 – 80 T2Dx Instrument Contracts LEXINGTON, Mass. , May 02, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.
04/18/19
Summary ToggleT2 Biosystems Announces 2019 First Quarter Financial and Operational Results Release and Conference Call Date Printer Friendly Version LEXINGTON, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it will release its 2019 first quarter financial and operational